Comparison of the use of calcium carbonate or acetate tablets with calcium carbonate emulsion in patients with chronic renal failure
Abstract
Hyperphosphatemia in chronic kidney disease (CKD) is associated with severe complications and increased morbidity and mortality. 95% of dialysis patients must use phosphate binders to its control. The poor tolerance and complications of these treatments, make difficult its compliance and effectiveness. This study compares the use of carbonate and / or calcium acetate tablets with an emulsion of calcium carbonate (CaC03) for the management of this hyperphosphatemia.
In 98 patients, the tablets (1250 mg CaC03 = 500 mg elemental calcium or 1000 mg calcium acetate = 250 mg elemental calcium), were replaced for CaC03 emulsion (1 dose = 1 tablespoon = 500 mg elemental calcium). At baseline and after three months, laboratory assessments and a satisfaction survey were performed. The daily dose of chelating agents was similar (4.5 ± 3.7 tablets; 4.2 ± 2.7 tablespoons of emulsion); phosphatemia and calcium-phosphorus product were significantly lower during the period with emulsion (5.8 ± 1.6 mg / dI and 51.9 ± 15.6 with tablets, 5.5 ± 1.5 mg / dI and 49.6 ± 15.0 with emulsion, p = 0.003); calcemia was not significant different. 79% of patients preferred the emulsion. 39.8% of patients admitted failing to comply with treatment with tablets; the dropout rate with the emulsion was 18%.
Thus, to chelate phosphorus, CaC03 emulsion was at least as effective as tablets; its better tolerance and acceptability make this formulation, an advantageous therapeutic option to consider.
References
Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl. 3):S112-9.
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607-17.
Negri AL. Nuevos quelantes de fósforo en el manejo de la hiperfosfatemia de la insuficiencia renal crónica. Rev Nefrol Diál y Transpl. 2003;58:13-8.
Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008;9:2.
Clarkson EM, Mc Donald SJ, De Wardener HE. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci. 1966;30(3):425-38.
Bro S, Rasmussen RA, Handberg J, Olgaard K, Feldt-Rasmussen B. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis. 1998;31(1):257-62.
Tan CC, Harden PN, Rodger RS, Rowe PA, Spooner RJ, Junor BJ, et al. Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant. 1996;11(5):851-3.
Osler P, Raniga P, Farrington K. Effect of omeprazole on the phosphate-binding capacity of calcium carbonate. Nephron 1995;69(1):89-90.
Pflanz S, Henderson IS, McElduff N, Jones MC. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant. 1994;9(8):1121-4.
Sperschneider H, Günther K, Marzoll I, Kirchner E, Stein G. Calcium carbonate (CaC03): An efficient and safe phosphate binder in haemodialysis patients? A 3-year study. Nephrol Dial Transplant. 1993; 8(6):530-4.
Oettinger CW, Oliver JC, Macon EJ. The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients. J Am Soc Nephrol. 1992;3(4):995-1001.
Malberti F, Surian M, Poggio F, Minoia C, Salvadeo A. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder. Am J Kidney Dis. 1988;12(6):487-91.
Slatopolsky E, Weerts C, Stokes T, Windus D, Delmez J. Alternative phosphate binders in dialysis patients: calcium carbonate. Semin Nephrol. 1986;6(4 Suppl 1):35-41.
Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med. 1986;315(3):157-61.
Taber TE, Hegemen TF, York S. Calcium carbonate as a phosphate binder in hemodialysis patients. ASAIO Trans. 1986;32(1):127-9.
Hercz G, Kraut JA, Andress DA, Howard N, Roberts C, Shinaberger JH, et al. Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab. 1986;12(5-6):314-9.
Djerad M, Morinière P, Westeel PF, el Esper N, Boitte F, Morsli R, et al. [Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia]. Nephrologie. 1991;12(4):193-7.
Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis. 1991;17(5):544-50.
Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J. 2004;25(6):785-91.
Brewster UC, Ciampi MA, Abu-Alfa AK, Reilly RF. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders. Nephrology (Carlton). 2006;11(2):142-6.
Suki WN; Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr. 2008;18(1):91-8.
Ben Hamida F, el Esper I, Compagnon M, Morinière P, Fournier A. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. Nephron. 1993;63(3):258-62.
Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol. 2010;23(5):525-34.
Nerbass FB, Morais JG, dos Santos RG, Krüger TS, Koene TT, da Luz Filho HA. Adherence and knowledge about hyperphosphatemia treatment in hemodialysis patients with hyperphosphatemia. Bras Nefrol. 2010;32(2):149-55.
